

February 25, 2026

TCG Lifesciences Private Limited: Ratings withdrawn

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long term – Fund based – Term loan	142.21	142.21	[ICRA]A- (Negative); Withdrawn
Long term – Fund based facilities**	(10.00)	(10.00)	[ICRA]A- (Negative); Withdrawn
Short term – Fund based facilities	140.00	140.00	[ICRA]A2+; Withdrawn
Short term – Non-fund based facilities	12.00	12.00	[ICRA]A2+; Withdrawn
Long term – Short term – Unallocated limits	6.42	6.42	[ICRA]A- (Negative)/ [ICRA]A2+; Withdrawn
Total	300.63	300.63	

*Instrument details are provided in Annexure I **Sublimit of short term – FB facilities

Rationale

ICRA has withdrawn the ratings assigned to the bank facilities of TCG Lifesciences Private Limited at the request of the company, based on the No Objection Certificate received from its bankers, and in accordance with ICRA's policy on withdrawal of credit ratings. ICRA does not have information to suggest that the credit risk has changed since the time the rating was last reviewed. The Key Rating Drivers and their description, Liquidity Position, Rating Sensitivities and Key financial indicators have not been captured as the rated instruments are being withdrawn. The previous detailed rating rationale is available at the following link: [Click Here](#)

Analytical approach

Analytical approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Pharmaceuticals Policy on Withdrawal of Credit Ratings
Parent/group Support	Not Applicable
Consolidation/standalone	While assigning the ratings, ICRA has taken a consolidated view of TCG Lifesciences Private Limited and TCG GreenChem Manufacturing Private Limited (formerly known as Clininvent Research Private Limited). The ratings are based on the consolidated financial profiles of the company. List of entities considered for consolidation are enlisted in Annexure II.

About the company

TCG Lifesciences Private Limited (TLPL), incorporated in 1998, provides contract research services, mainly for early-stage drug discovery and development. The company provides services for chemical synthesis of small molecules, first-level screening of drugs (in-vitro testing) and small animal testing.

TLPL is promoted by The Chatterjee Group, which was founded by Dr. Purnendu Chatterjee in 1989. The Group has diversified interests in investment banking, life sciences and pharmaceuticals, real estate, petrochemicals, hedge fund and wealth management products. It also provides outsourcing and technology services, including BPO services, and is present in the US, Europe and South Asia. It is headquartered in New York.

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for past three years

Instrument	Type	Current rating (FY2026)		Chronology of rating history for the past 3 years					
		Amount rated (Rs. crore)	February 25, 2026	FY2025		FY2024		FY2023	
				Date	Rating	Date	Rating	Date	Rating
Interchangeable limits- Others**	Long Term	(10.00)	[ICRA]A- (Negative); withdrawn	Apr 05, 2024	[ICRA]A (Negative)	-	-	Mar 30, 2023	[ICRA]A (Stable)
				Mar 11, 2025	[ICRA]A- (Negative)	-	-	-	-
Unallocated limits	Long Tem/ Short Term	6.42	[ICRA]A- (Negative)/ [ICRA]A2+; withdrawn	Apr 05, 2024	[ICRA]A (Negative)/ [ICRA]A1	-	-	Mar 30, 2023	[ICRA]A (Stable)/ [ICRA]A1
				Mar 11, 2025	[ICRA]A- (Negative)/ [ICRA]A2+	-	-	-	-
Fund-based-Term loan	Long Term	142.21	[ICRA]A- (Negative); withdrawn	Apr 05, 2024	[ICRA]A (Negative)	-	-	Mar 30, 2023	[ICRA]A (Stable)
				Mar 11, 2025	[ICRA]A- (Negative)	-	-	-	-
Fund-based-Others	Short Term	140.00	[ICRA]A2+; withdrawn	Apr 05, 2024	[ICRA]A1	-	-	-	-
				Mar 11, 2025	[ICRA]A2+	-	-	-	-
Non-fund based-Others	Short Term	12.00	[ICRA]A2+; withdrawn	Apr 05, 2024	[ICRA]A1	-	-	Mar 30, 2023	[ICRA]A1
				Mar 11, 2025	[ICRA]A2+	-	-	-	-

**Sublimit of short term – FB facilities

Complexity level of the rated instruments

Instrument	Complexity indicator
Long term – Fund-based – Term loan	Simple
Long term – Fund-based facilities	Simple
Short term – Fund-based facilities	Simple
Short term – Non-fund based facilities	Simple
Long term – Short term – Unallocated limits	Not Applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click here](#)

Annexure I: Instrument details

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook
NA	Long term – Fund-based – Term loan	FY2024-FY2025	-	Upto FY2031	142.21	[ICRA]A- (Negative); Withdrawn
NA	Long term – Fund-based facilities**	-	-	-	(10.00)	[ICRA]A- (Negative); Withdrawn
NA	Short term – Fund-based facilities	-	-	-	140.00	[ICRA]A2+; Withdrawn
NA	Short term – Non-fund based facilities	-	-	-	12.00	[ICRA]A2+; Withdrawn
NA	Long term – Short term – Unallocated limits	-	-	-	6.42	[ICRA]A- (Negative)/ [ICRA]A2+; Withdrawn

Source: Company; **Sublimit of short term – FB facilities

[Please Click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis

Company name	TCGL's ownership	Consolidation approach
TCG GreenChem Manufacturing Private Limited (Formerly, Clininvent Research Private Limited)	100.00%	Full Consolidation
X-tec International (Mauritius) Limited	100.00%	Full Consolidation
TCG Centre for Research and Technology (Formerly, Global Institute of Science and Technology)	20.00%	Equity Method

Source: TCGL annual report FY2024

ANALYST CONTACTS

Jitin Makkar

+91 124 4545 368

jitinm@icraindia.com

Kinjal Kirit Shah

+91 22 6114 3442

kinjal.shah@icraindia.com

Sujoy Saha

+91 33 6521 6805

sujoy.saha@icraindia.com

Sandipan Kumar Das

+91 33 6521 6807

sandipan.das@icraindia.com

RELATIONSHIP CONTACT

L Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited




Registered Office

B-710, Statesman House 148, Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45



Branches



© Copyright, 2026 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.